Cuba Talks Parkinson Disease Prensa Latina, Cuba - 22 minutes ago ... de Restauracion Neurologica (CIREN), a 13-year world pioneer in selective subtalamotomy, so far the most efficient treatment for Parkinson?s disease. ...
Don?t Fire Until You See the Whites of Their Eyes The Epoch Times, NY - It affects close to 300000 Canadians, more Canadians than those who have breast cancer, prostate cancer, Parkinson?s disease, and Alzheimer?s disease...
Biotech faces a bitter season Austin American-Statesman, TX - ... moved to smaller offices to conserve the $6.5 million it has on hand; and is delaying research on drugs for Alzheimer's disease and Parkinson's disease, ...
Gala evening at the movies Mirror, MI - Western Oakland Parkinson Support Group meets 709 pm on the second Tuesday of the month except January, July and August, at Farmington Hills Baptist Church, ...
Uganda national's medical hospitalization for parkinson?s disease... PRLog.Org (press release), Romania - Nov 25, 2008 PRLog (Press Release) ? Nov 25, 2008 ? A Uganda national named Jawanza Perry got medical hospitalization for Parkinson?s disease treatment at Bangalore in ...
Source: Google News
Recent News and Articles on the Keywords: dementia treatment + s treatment + dementia Related to the article below (Last Update: 8/7/2008)
Innovative Alzheimer's medications offer hope Connecticut Post, CT - I will try to summarize them for you, but first let me briefly describe what is available for treatment of dementia now. First, no new drugs for dementia...
Bay Pines treatment program is a model in Florida WMNF, FL - Aug 5, 2008 Though there is no cure for cognitive impairments, research has shown mental stimulation offered at dementia day treatment centers prolongs the time a ...
Kidney patients denied 'too expensive' life-extending drugs Telegraph.co.uk, United Kingdom - In May, the Court of Appeal ruled that Nice had been procedurally unfair in refusing to give anti-dementia medicines such as Aricept, costing about ?2.50 a ...
Dementia the topic Tyger Burger, South Africa - As the play was written from personal experience, it also deals with Finuala?s own emotions. She wrote: ?I think I reserve my harshest treatment for her ...
To Be Old, Frail Wall Street Journal - Residents with dementia or demanding families are among the most vulnerable, particularly if -- like Ms. Nguyen and the other Lodi residents -- they depend ...
New Drug May Help Combat Alzheimer's Emediawire (press release), WA - ... word finding, and aphasia in Alzheimer's disease and related forms of dementia following initiation of a new immune treatment is reported. ...
Avoid baby talk in dementia care Nursing Times, UK - Nurses should refrain from using baby talk with patients who have Alzheimer's disease as it leads to less cooperation over treatment and care, ...
Source: Google News
A metaanalysis of controlled trials of neuroleptic treatment in dementia. LS Schneider, VE Pollock, SA Lyness - J Am Geriatr Soc, 1990 - ncbi.nlm.nih.gov J Am Geriatr Soc. 1990 May;38(5):553-63. A metaanalysis of controlled trials of
neuroleptic treatment in dementia. Schneider LS, Pollock VE, Lyness SA. ...
Behavioral treatment of depression in dementia patients: a controlled clinical trial - L Teri, RG Logsdon, J Uomoto, SM McCurry - Journals of Gerontology Series B: Psychological Sciences and …, 1997 - Geron Soc America ... Patients in both behavioral treatment conditions showed significant ... to Help Family
Members Improve Dementia Care: A ... Home page R. Schulz, A. O'Brien, S. Czaja, M ...
Zidovudine treatment of the AIDS dementia complex: Results of a placebo-controlled trial - JJ Sidtis, C Gatsonis, RW Price, EJ Singer, AC … - Annals of Neurology, 1993 - doi.wiley.com ... The patient?s Karnofsky per- formance score [lo] was ... im- pressions of the severity
of dementia, motor abnormality ... for the analy- ses of treatment efficacy. ...
Parkinson’s disease: Exelon for treatment of dementia
The FDA ( Food and Drug Administration ) has approved Exelon ( Rivastigmine ) for the treatment of mild to moderate dementia associated with Parkinson's disease.
Exelon was previously approved for the treatment of mild to moderate dementia of the Alzheimer's type.
The approval of Exelon for the treatment of Parkinson's dementia is based on the results of a randomized, placebo-controlled clinical study with 541 patients who showed symptoms of mild to moderate dementia two years or later after their diagnosis for Parkinson's disease.
At the end of the 24-week trial, the condition of the Exelon-treated patients, as shown on a scale that measures mental processes, was significantly better than the condition of the patients on placebo.
The use of Exelon has been associated with significant gastrointestinal adverse reactions.
In clinical trials, 47 percent of the patients treated with the drug developed nausea, and 26 percent of women and 18 percent of men on high doses of Exelon experienced significant weight loss.
Other common adverse events reported by patients on Exelon include vomiting, anorexia, dyspepsia and asthenia.
In some patients with Parkinson's disease, treatment with Exelon was associated with a worsening of tremor.
